Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension

Journal of Human Hypertension

Volumn 22, Issue 7, 2008, Pages 493-500

  Labios M ^a   Martinez M ^b   Gabriel, F ^a   Guiral, V ^a   Ruiz Aja, S ^b   Beltran B ^b   Munoz A ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c Solvay Pharma   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CD3 ANTIGEN; CD4 ANTIGEN; DICHLOROFLUORESCEIN; EPROSARTAN; HYDROGEN PEROXIDE; TERT BUTYL HYDROPEROXIDE; TETRAMETHYLRHODAMINE METHYL ESTER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE REGULATION; CELL ASSAY; CELL STRUCTURE; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN CELL; HYPERTENSION; INCUBATION TIME; LEUKOCYTE; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PATHOGENESIS; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TEMPERATURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VENOUS BLOOD;

ACRYLATES; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYDROGEN PEROXIDE; HYPERTENSION; IMIDAZOLES; LEUKOCYTES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; RHODAMINES; TERT-BUTYLHYDROPEROXIDE; THIOPHENES;

EID: 45849147670     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.19     Document Type: Article

References (34)

1. Kim CH, Vaziri ND. Hypertension promotes integrin expression and reactive oxygen species generation by circulating leucocytes. Kidney Int 2005; 67: 1462-1470.
2. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1954-1962.
3. Shen K, DeLano FA, Zweifach BW, Schmid-Schonbein GW. Circulating leucocytes counts, activation, and degranulation in Dahl hypertensive rats. Circ Res 1995; 76: 276-283.
4. Dorffel Y, Latsch C, Stuilmuller B, Schreiber S, Scholze S, Burmester GR et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113-117.
5. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leucocytes is a possible link between blood pressure, blood glucose, and C-reactive protein. Hypertension 2002; 39: 777-780.
6. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000; 29: 222-230.
7. Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 1973; 134: 707-716.
8. Salvador A, Sousa J, Pinto RE. Hydroperoxyl, superoxide and pH gradients in the mitochondrial matrix: A theoretical assessment. Free Radic Biol Med 2001; 1: 1208-1215.
9. Nulton-Persson AC, Szweda LI. Modulation of mitochondrial function by hydrogen peroxide. J Biol Chem 2001; 276: 23357-23361.
10. Kowaltowski AJ, Vercesi AH. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999; 26: 463-471.
11. Teveten (Eprosartan) Summary of Product Characteristics. Solvay Healthcare Limited: Southampton, UK, 2006.
12. Manabe S, Takafumi O, Watanabe S, Fukuoka T, Jitsuo H. Effects of angiotensin II receptor blockade with valsartan on proinflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46: 735-739.
13. Huang SG. Development of a high throughput screening assay for mitochondrial membrane potential in living cells. J Biomol Screen 2002; 7: 383-389.
14. Scaduto RC, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 1999; 76: 469-477.
15. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2′,7′-dichlorofluoreseein as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992; 5: 227-231.
16. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: A graded response to membrane stimulation. J Immunol 1983; 130 1910-1917.
17. Vaziri ND, Rodríguez-Iturbe B. Mechanisms of disease: Oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2: 582-593.
18. Hafliwell B. Reactive oxygen species in living systems: Source, biochemistry, and role in human disease. Am J Med 1999; 91 Suppl 3C): 14S-22S.
19. Crakowki JL, Baguet JP, Ormezzano O, Bessard J, Stanke-Labesque F, Bessard G et al. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension 2003; 41: 286-288.
20. Abeles FB. Plant chemiluminescence. Ann Rev Plant Physiol 1986; 37: 49-72.
21. Lacy F, O'Connor DT, Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 1998; 16: 291-303.
22. Karnovsky ML. The metabolism of leucocytes. Semin Hematol 1968; 5: 156-159.
23. Fossati G, Moulding DA, Spiller DG, Moots RJ, White MRH, Edwards SW. The mitochondrial network of human neutrophils: Role in chemotaxis, phagocytosis, respiratory burst activation, and commitment to apoptosis. J Immunol 2003; 170: 1964-1972.
24. El Bekay R, Alvarez M, Monteseirin J, Alba G, Chacón P, Vega A et al. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: Involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NK-κB. Blood 2003; 102: 662-671.
25. Schmeisser A, Soehnlein O, Illmer T, Lorenz HM, Eskafi S, Roerick O et al. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappa B activity and AT1 receptor expression. Biochem Biophys Res Commun 2004; 352: 532-540.
26. Kim JA, Berliner JA, Nadler JR. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996; 226: 862-868.
27. Labiós M, Martínez M, Gabriel F, Guiral V, Muñoz A, Aznar J. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. Am J Hypertens 2004: 17: 757-763.
28. Li N, Hu H, Lindqvist M, Wikström-Jonsson E, Goodall AH, Hjemdahl P. Platelet-leucocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702-7208.
29. Bazzoni G, Dejana E, Del Maschio A. Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica 1991; 76: 491-499.
30. Lijnen P, Fagard R, Petrov V. Cytosolic calcium changes induced by angiotensin II in human peripheral blood mononuclear cells are mediated via angiotensin II subtype 1 receptors. J Hypertens 1997; 15 871-876.
31. Sela S, Shurtz-Swirski R, Farah R, Levy R, Shapiro G, Chezar J et al A link between polymorphonuclear leucocyte intracetlular calcium, plasma insulin, and essential hypertension. Am J Hypertens 2002; 15: 291-295.
32. Simic DV, Mimik-Oka J, Pljesa-Ercegovac M, Savic-Radojevic A, Opacic M, Matic D et al. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. J Hum Hypertens 2006; 20: 149-155.
33. Germanó S, Sanguigni V, Pignatelli P, Caccese D, Lenti L, Ragazzo M et al. Enhanced platelet release of superoxide anion in systemic hypertension: Role of AT1 receptors. J Hypertens 2004; 22: 1085-1086.
34. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A et al Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 1999; 44: 215-222.